- £3.60bn
- £4.86bn
- $3.35bn
Brief: Hikma Launches Tofacitinib Oral Solution In The U.S.
Hikma Pharmaceutical - Director/PDMR Shareholding
Brief: Hikma Pharmaceuticals Announces Major Expansion In Ohio, Creating 350 New Jobs And Investing $267 Million
Hikma Pharmaceutical - Director/PDMR Shareholding
Europe Research Roundup: Burberry, Hochtief, Volex
US appeals court revives Amarin heart-drug patent lawsuit over Hikma generic - June 25, 2024
US Supreme Court hears patent case with potentially sweeping implications for generics
BridgeBio slips as Pfizer patent deal disappoints investors
Pfizer secures deals to keep heart drug free of generic rivals until 2031 (updated)
Brief: Pfizer reaches settlement agreements with Dexcel Pharma, Hikma & Cipla for Vyndamax
Hikma Pharmaceutical - Director/PDMR Shareholding
Brief: Hikma Says All AGM Resolutions Passed By Shareholders
UK Stocks-Factors to watch on April 23 (updated)
UK's Hikma Pharmaceuticals keeps 2026 outlook, confident in managing Mideast war costs (updated)
UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war
Brief: Hikma Says Demand In Middle East Region Remains Robust & Group Continues To Maintain Sufficient Inventory Levels
Hikma Pharmaceutical - Trading Statement
UK Stocks-Factors to watch on April 23
Hikma Pharmaceutical - Director/PDMR Shareholding